SCHEMBL30613656

SCHEMBL30613656

Cc1ccnc2c1C(=O)NC(=O)C2

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP2 O95551 7/20 0.37
GRIA1 P42261 1/20 0.36
CACNG8 Q8WXS5 1/20 0.36
NOS3 P29474 2/20 0.33
NOS2 P35228 2/20 0.33
PDE3A Q14432 2/20 0.33
MAPT P10636 2/20 0.33
CASP3 P42574 1/20 0.33
CASP7 P55210 1/20 0.33
CASP9 P55211 1/20 0.33
CASP6 P55212 1/20 0.33
CASP8 Q14790 1/20 0.33
MAP3K14 Q99558 1/20 0.33
PDE3B Q13370 1/20 0.33
ALDH1A1 P00352 1/20 0.33
LMNA P02545 1/20 0.33
POLB P06746 1/20 0.33
ADORA3 P0DMS8 1/20 0.33
MAPK1 P28482 1/20 0.33
ADORA2A P29274 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26135340 1.00 TDP2 (0.37) TDP2GRIA1CACNG8NOS3NOS2
SCHEMBL659718 0.79 PDE3A (0.37) GRIA1CACNG8NOS3NOS2PDE3A
SCHEMBL19032178 0.77 NOS2 (0.36) NOS3NOS2PDE3AALDH1A1LMNA
SCHEMBL26135520 0.76 TDP2 (0.38) TDP2GSK3BCDK5
SCHEMBL30613724 0.76 TDP2 (0.38) TDP2GSK3BCDK5
SCHEMBL9961393 0.74 PDE4B (0.43) CHEK1DAPK3PRKD3MAP4K4CSF1R
SCHEMBL2398708 0.73 SRC (0.42) PDE3AMAPTPDE3BCHEK1AURKA
SCHEMBL22904110 0.71 CHEK1 (0.35) TDP2MAPTCASP3CASP7CASP9
SCHEMBL22904363 0.69 TDP2 (0.47) TDP2NOS3NOS2PDE3ACASP3
SCHEMBL27404232 0.68 NOS2 (0.39) NOS3NOS2CCR1CCR5CCR8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250263408-A1 SPLEEN TYROSINE KINASE INHIBITORS UNIQUEST PTY LTD (AU) 2025-08-21 US disclosed
EP-4504724-A1 SPLEEN TYROSINE KINASE INHIBITORS Uniquest Pty Limited (AU) 2025-02-12 EP disclosed
CN-119325474-A Spleen tyrosine kinase inhibitors 尤尼奎斯特公司 2025-01-17 CN disclosed
WO-2023193054-A1 SPLEEN TYROSINE KINASE INHIBITORS UNIQUEST PTY LTD (AU) 2023-10-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250263408-A1 SPLEEN TYROSINE KINASE INHIBITORS LCK, BTK, SYK TDP2 1093/4885GRIA1 1608/4885CACNG8 3420/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.